High-dose chemotherapy with bone marrow or peripheral blood progenitor cell (PBPC) transplantation is no longer used.
A 2011 overview of six randomized trials concluded: Overall survival of patients with metastatic breast cancer in the six randomized trials was not significantly improved by high-dose chemotherapy; any benefit from high doses was small.